BML, Inc.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Major Holders
Updated 2026/01/11| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
MFS Series Trust V-MFS International New Discovery Fund
|
864.2K | 0.00% | |
|
HARTFORD MUTUAL FUNDS INC/CT-The Hartford International Value Fund
|
442.8K | -0.52% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
310.2K | +1.67% | |
|
Putnam Investment Fd.s-Putnam Intl Capital Opportunities Fd.
|
238.2K | +33.82% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
199.8K | +3.79% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
135.6K | 0.00% |
Dividend History 1Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥130 | +44.4% |
| 2024 | ¥90 | -10.0% |
| 2023 | ¥100 | -20.0% |
| 2022 | ¥125 | +47.1% |
| 2021 | ¥85 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥186,067M | ¥159,462M | ¥137,964M | ¥143,191M |
| Gross Profit | ¥86,951M | ¥61,446M | ¥45,628M | ¥45,861M |
| Operating Income | ¥48,890M | ¥23,937M | ¥9,167M | ¥9,364M |
| Pretax Income | ¥50,364M | ¥24,224M | ¥9,627M | ¥9,791M |
| Net Income | ¥33,741M | ¥15,578M | ¥6,034M | ¥6,263M |
| EPS | ¥832.62 | ¥395.62 | ¥154.74 | ¥160.55 |
| Operating Margin | 26.28% | 15.01% | 6.64% | 6.54% |
| Balance Sheet | ||||
| Total Assets | ¥179,200M | ¥168,943M | ¥170,991M | ¥177,507M |
| Total Equity | ¥116,196M | ¥122,488M | ¥125,864M | ¥129,400M |
| Total Liabilities | ¥63,004M | ¥46,455M | ¥45,127M | ¥48,107M |
| Cash | ¥92,126M | ¥86,521M | ¥74,114M | ¥67,562M |
| Interest-bearing Debt | ¥3,330M | ¥4,150M | ¥5,265M | ¥5,289M |
| Equity Ratio | 64.84% | 72.50% | 73.61% | 72.90% |
| D/E Ratio | 0.03 | 0.03 | 0.04 | 0.04 |
| Cash Flow | ||||
| Operating CF | ¥45,603M | ¥11,742M | ¥14,446M | ¥15,809M |
| Investing CF | -¥7,297M | -¥7,627M | -¥21,137M | -¥16,793M |
| Financing CF | -¥9,828M | -¥9,715M | -¥5,733M | -¥5,426M |
| Free CF | ¥38,518M | ¥5,282M | -¥6,481M | -¥849M |
| Efficiency | ||||
| ROE | 29.04% | 12.72% | 4.79% | 4.84% |
| ROA | 18.83% | 9.22% | 3.53% | 3.53% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4694
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥4,200
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
